Psycho-oncology · 2025
Development and Validation of a Rapid Screening Measure for Mask Anxiety in Head and Neck Cancer Patients Undergoing Radiotherapy.
СтатьяВалидационное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pelland Marie-Ève, Lagadec-Gaulin Laurence, Bahig Houda, Filion Edith, Lambert Louise, Nguyen-Tan Phuc Felix, Foldes-Busque Guillaume
Аннотация
OBJECTIVE: This study aims to develop a brief screening questionnaire for early identification of radiotherapy mask-related anxiety in patients with head and neck cancer.
METHODS: A cross-sectional study recruited 512 patients undergoing radiotherapy between April 2016 and February 2021. Participants completed a screening questionnaire assessing mask-related anxiety and were assessed for anxious response during CT or MRI planning scans. A subgroup completed the Claustrophobia Questionnaire (CLQ) for comparison. Data were analyzed using multivariate logistic regression and discriminant validity was evaluated using the area under the ROC curve (AUROC).
RESULTS: The study developed the Radiotherapy Mask Anxiety Questionnaire (R-MAQ), consisting of four items, derived from the screening questionnaire, which showed good model fit (Hosmer-Lemeshow p = 0.92) and predictive accuracy (AUROC = 0.78). Of the 410 participants (mean age 62), 27.3% presented an anxious response to the immobilization mask during planning exams. The R-MAQ demonstrated comparable or superior validity to the CLQ and effectively identified patients at risk of radiotherapy mask-related anxiety.
CONCLUSIONS: The R-MAQ is a valid and efficient tool for identifying patients at risk of mask-related anxiety during radiotherapy for head and neck cancer. It offers a clinically relevant, context-specific method for early intervention, potentially improving treatment adherence and outcomes. Future research should explore its broader applicability and impact on treatment efficacy.
METHODS: A cross-sectional study recruited 512 patients undergoing radiotherapy between April 2016 and February 2021. Participants completed a screening questionnaire assessing mask-related anxiety and were assessed for anxious response during CT or MRI planning scans. A subgroup completed the Claustrophobia Questionnaire (CLQ) for comparison. Data were analyzed using multivariate logistic regression and discriminant validity was evaluated using the area under the ROC curve (AUROC).
RESULTS: The study developed the Radiotherapy Mask Anxiety Questionnaire (R-MAQ), consisting of four items, derived from the screening questionnaire, which showed good model fit (Hosmer-Lemeshow p = 0.92) and predictive accuracy (AUROC = 0.78). Of the 410 participants (mean age 62), 27.3% presented an anxious response to the immobilization mask during planning exams. The R-MAQ demonstrated comparable or superior validity to the CLQ and effectively identified patients at risk of radiotherapy mask-related anxiety.
CONCLUSIONS: The R-MAQ is a valid and efficient tool for identifying patients at risk of mask-related anxiety during radiotherapy for head and neck cancer. It offers a clinically relevant, context-specific method for early intervention, potentially improving treatment adherence and outcomes. Future research should explore its broader applicability and impact on treatment efficacy.